A Study of TAK-861 in People With Narcolepsy Type 1

PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

June 4, 2025

Study Completion Date

June 4, 2025

Conditions
Narcolepsy Type 1
Interventions
DRUG

TAK-861

Oral tablet.

DRUG

Placebo

TAK-861-matching placebo tablet.

Trial Locations (28)

380

Takeda Site 20, Helsinki

3000

Takeda Site 24, Leuven

3080

Takeda Site 12, Seoul

4000

Takeda Site 23, Liège

4020

Takeda Site 22, Linz

5101

Takeda Site 3, Erpent

9000

Takeda Site 25, Ghent

13385

Takeda Site 14, Marseille

16247

Takeda Site 10, Suwon

33076

Takeda Site 16, Léon

33520

Takeda Site 21, Tampere

40139

Takeda Site 7, Bologna

41931

Takeda Site 11, Seoul

44093

Takeda Site 15, Nantes

86077

Takeda Site 17, Pozzilli

Unknown

Takeda Site 1, Glebe

Takeda Site 2, Alken

Takeda Site 4, Beijing

Takeda Site 27, Zhengzhou

Takeda Site 28, Shanghai

Takeda Site 26, Guangdong

Takeda Site 6, Bron

Takeda Site 5, Montpellier

Takeda Site 8, Roma

Takeda Site 9, Krakow

Takeda Site 13, Madrid

Takeda Site 19, Uppsala

08035

28003, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY